Trait: systolic blood pressure

Experimental Factor Ontology (EFO) Information
Identifier EFO_0006335
Description The blood pressure during the contraction of the left ventricle of the heart.
Trait category
Other measurement
Synonyms 2 synonyms
  • SYSBP
  • systolic pressure
Mapped terms 3 mapped terms
  • MedDRA:10042955
  • NCIt:C25298
  • SNOMEDCT:271649006

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported
Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution Scoring File (FTP Link)
PGS000301
(GRS970_SBP)
PGP000092 |
Xie T et al. Circ Genom Precis Med (2020)
Systolic blood pressure systolic blood pressure 970
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000301/ScoringFiles/PGS000301.txt.gz
PGS000900
(PRS_SBP_f)
PGP000233 |
Kauko A et al. Hypertension (2021)
Systolic blood pressure (female) systolic blood pressure,
female
1,098,015
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000900/ScoringFiles/PGS000900.txt.gz
PGS000901
(PRS_SBP_m)
PGP000233 |
Kauko A et al. Hypertension (2021)
Systolic blood pressure (male) systolic blood pressure,
male
1,098,015
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000901/ScoringFiles/PGS000901.txt.gz
PGS000913
(ukb_sbp_prs)
PGP000240 |
Vaura F et al. Hypertension (2021)
Systolic blood pressure systolic blood pressure 1,098,015
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000913/ScoringFiles/PGS000913.txt.gz
PGS001134
(GBE_INI4080)
PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
Systolic BP (AR) systolic blood pressure 15,481
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001134/ScoringFiles/PGS001134.txt.gz
PGS002009
(portability-PLR_systolic_BP)
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Systolic blood pressure, automated reading systolic blood pressure 68,449
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002009/ScoringFiles/PGS002009.txt.gz
PGS002228
(portability-ldpred2_systolic_BP)
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Systolic blood pressure, automated reading systolic blood pressure 937,030
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002228/ScoringFiles/PGS002228.txt.gz
PGS002257
(GRS901_SBP)
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Systolic blood pressure systolic blood pressure 884
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002257/ScoringFiles/PGS002257.txt.gz
PGS002275
(SBP-PRS)
PGP000303 |
Groenland EH et al. Atherosclerosis (2022)
Systolic blood pressure systolic blood pressure 425
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002275/ScoringFiles/PGS002275.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
Evaluated Score PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM000801 PGS000301
(GRS970_SBP)
PSS000371|
European Ancestry|
288 individuals
PGP000092 |
Xie T et al. Circ Genom Precis Med (2020)
Reported Trait: Systolic blood pressure (mmHg) : 0.012 Sex, age, age^2, BMI
PPM000771 PGS000301
(GRS970_SBP)
PSS000376|
European Ancestry|
1,354 individuals
PGP000092 |
Xie T et al. Circ Genom Precis Med (2020)
Reported Trait: Systolic blood pressure (mmHg) : 0.0215 Sex, age, age^2, BMI
PPM002648 PGS000900
(PRS_SBP_f)
PSS001169|
European Ancestry|
123,579 individuals
PGP000233 |
Kauko A et al. Hypertension (2021)
Reported Trait: Hypertension HR: 1.42 [1.4, 1.44] Hazard Ratio (HR, top 2.5% vs middle 60%): 2.12 [1.99, 2.25] Age as timescale, collection year, genotyping batch, PCs(1-10)
PPM002650 PGS000900
(PRS_SBP_f)
PSS001169|
European Ancestry|
123,579 individuals
PGP000233 |
Kauko A et al. Hypertension (2021)
Reported Trait: Early-onset hypertension (< 55 years) HR: 1.56 [1.53, 1.58] Hazard Ratio (HR, top 2.5% vs middle 60%): 2.51 [2.32, 2.72] Age as timescale, collection year, genotyping batch, PCs(1-10)
PPM002652 PGS000900
(PRS_SBP_f)
PSS001169|
European Ancestry|
123,579 individuals
PGP000233 |
Kauko A et al. Hypertension (2021)
Reported Trait: Late-onset hypertension (> 55 years) HR: 1.31 [1.28, 1.33] Hazard Ratio (HR, top 2.5% vs middle 60%): 1.66 [1.5, 1.84] Age as timescale, collection year, genotyping batch, PCs(1-10)
PPM002649 PGS000901
(PRS_SBP_m)
PSS001170|
European Ancestry|
95,213 individuals
PGP000233 |
Kauko A et al. Hypertension (2021)
Reported Trait: Hypertension HR: 1.27 [1.26, 1.29] Hazard Ratio (HR, top 2.5% vs middle 60%): 1.8 [1.69, 1.92] Age as timescale, collection year, genotyping batch, PCs(1-10)
PPM002651 PGS000901
(PRS_SBP_m)
PSS001170|
European Ancestry|
95,213 individuals
PGP000233 |
Kauko A et al. Hypertension (2021)
Reported Trait: Early-onset hypertension (< 55 years) HR: 1.35 [1.32, 1.37] Hazard Ratio (HR, top 2.5% vs middle 60%): 2.1 [1.94, 2.28] Age as timescale, collection year, genotyping batch, PCs(1-10)
PPM002653 PGS000901
(PRS_SBP_m)
PSS001170|
European Ancestry|
95,213 individuals
PGP000233 |
Kauko A et al. Hypertension (2021)
Reported Trait: Late-onset hypertension (> 55 years) HR: 1.21 [1.19, 1.23] Hazard Ratio (HR, top 2.5% vs middle 60%): 1.45 [1.3, 1.61] Age as timescale, collection year, genotyping batch, PCs(1-10)
PPM002970 PGS000913
(ukb_sbp_prs)
PSS001446|
European Ancestry|
218,754 individuals
PGP000240 |
Vaura F et al. Hypertension (2021)
Reported Trait: Early onset incident hypertension (< 55 years) HR: 1.54 [1.53, 1.56] Hazard Ratio (HR, top 2.5% vs middle 60%): 2.62 [2.48, 2.77] Sex, collection year, genotyping batch, PCs(1-10)
PPM002971 PGS000913
(ukb_sbp_prs)
PSS001446|
European Ancestry|
218,754 individuals
PGP000240 |
Vaura F et al. Hypertension (2021)
Reported Trait: Late onset incident hypertension (≥55 years) HR: 1.31 [1.29, 1.32] Hazard Ratio (HR, top 2.5% vs middle 60%): 1.68 [1.57, 1.81] Sex, collection year, genotyping batch, PCs(1-10)
PPM002977 PGS000913
(ukb_sbp_prs)
PSS001448|
European Ancestry|
218,792 individuals
PGP000240 |
Vaura F et al. Hypertension (2021)
Reported Trait: Incident cardiovascular disease Hazard Ratio (HR, top 2.5% vs middle 60%): 1.3 [1.22, 1.39] Sex, collection year, genotyping batch, PCs(1-10)
PPM002978 PGS000913
(ukb_sbp_prs)
PSS001447|
European Ancestry|
218,792 individuals
PGP000240 |
Vaura F et al. Hypertension (2021)
Reported Trait: Incident coronary heart disease HR: 1.15 [1.13, 1.17] Hazard Ratio (HR, top 2.5% vs middle 60%): 1.33 [1.23, 1.44] Sex, collection year, genotyping batch, PCs(1-10)
PPM002979 PGS000913
(ukb_sbp_prs)
PSS001449|
European Ancestry|
212,884 individuals
PGP000240 |
Vaura F et al. Hypertension (2021)
Reported Trait: Incident stroke Hazard Ratio (HR, top 2.5% vs middle 60%): 1.29 [1.16, 1.44] Sex, collection year, genotyping batch, PCs(1-10)
PPM002981 PGS000913
(ukb_sbp_prs)
PSS001447|
European Ancestry|
218,792 individuals
PGP000240 |
Vaura F et al. Hypertension (2021)
Reported Trait: Incident coronary heart disease C-index: 0.743 Clinical atherosclerotic cardiovascular disease risk score (age, sex, total cholesterol, high density lipoprotein, antihypertensive medication, diabetes, current smoking)
PPM002982 PGS000913
(ukb_sbp_prs)
PSS001449|
European Ancestry|
212,884 individuals
PGP000240 |
Vaura F et al. Hypertension (2021)
Reported Trait: Incident stroke C-index: 0.732 Clinical atherosclerotic cardiovascular disease risk score (age, sex, total cholesterol, high density lipoprotein, antihypertensive medication, diabetes, current smoking)
PPM002969 PGS000913
(ukb_sbp_prs)
PSS001446|
European Ancestry|
218,754 individuals
PGP000240 |
Vaura F et al. Hypertension (2021)
Reported Trait: Incident hypertension HR: 1.42 [1.41, 1.43] Hazard Ratio (HR, top 2.5% vs middle 60%): 2.19 [2.1, 2.29] Sex, collection year, genotyping batch, PCs(1-10)
PPM002975 PGS000913
(ukb_sbp_prs)
PSS001450|
European Ancestry|
9,906 individuals
PGP000240 |
Vaura F et al. Hypertension (2021)
Reported Trait: Incident hypertension C-index: 0.802 Age, sex, systolic blood pressure, diastolic blood pressure, body mass index, diabetes, current smoking
PPM002980 PGS000913
(ukb_sbp_prs)
PSS001448|
European Ancestry|
218,792 individuals
PGP000240 |
Vaura F et al. Hypertension (2021)
Reported Trait: Incident cardiovascular disease C-index: 0.731 Clinical atherosclerotic cardiovascular disease risk score (age, sex, total cholesterol, high density lipoprotein, antihypertensive medication, diabetes, current smoking)
PPM008400 PGS001134
(GBE_INI4080)
PSS007268|
European Ancestry|
23,726 individuals
PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
Reported Trait: Systolic BP (AR) : 0.19444 [0.18561, 0.20326]
Incremental R2 (full-covars): 0.04167
PGS R2 (no covariates): 0.04458 [0.03957, 0.04959]
age, sex, UKB array type, Genotype PCs
PPM008398 PGS001134
(GBE_INI4080)
PSS007266|
African Ancestry|
6,409 individuals
PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
Reported Trait: Systolic BP (AR) : 0.1028 [0.08882, 0.11678]
Incremental R2 (full-covars): 0.00145
PGS R2 (no covariates): 0.00628 [0.00245, 0.01011]
age, sex, UKB array type, Genotype PCs
PPM008399 PGS001134
(GBE_INI4080)
PSS007267|
East Asian Ancestry|
1,634 individuals
PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
Reported Trait: Systolic BP (AR) : 0.22915 [0.19418, 0.26412]
Incremental R2 (full-covars): 0.03474
PGS R2 (no covariates): 0.04463 [0.0255, 0.06375]
age, sex, UKB array type, Genotype PCs
PPM008401 PGS001134
(GBE_INI4080)
PSS007269|
South Asian Ancestry|
7,640 individuals
PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
Reported Trait: Systolic BP (AR) : 0.15314 [0.13847, 0.16782]
Incremental R2 (full-covars): 0.02459
PGS R2 (no covariates): 0.0236 [0.01696, 0.03024]
age, sex, UKB array type, Genotype PCs
PPM008402 PGS001134
(GBE_INI4080)
PSS007270|
European Ancestry|
63,823 individuals
PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
Reported Trait: Systolic BP (AR) : 0.17232 [0.16713, 0.17751]
Incremental R2 (full-covars): 0.04845
PGS R2 (no covariates): 0.04834 [0.04519, 0.0515]
age, sex, UKB array type, Genotype PCs
PPM010946 PGS002009
(portability-PLR_systolic_BP)
PSS009494|
European Ancestry|
18,717 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Systolic blood pressure, automated reading Partial Correlation (partial-r): 0.2548 [0.2414, 0.2682] sex, age, birth date, deprivation index, 16 PCs
PPM010947 PGS002009
(portability-PLR_systolic_BP)
PSS009268|
European Ancestry|
3,930 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Systolic blood pressure, automated reading Partial Correlation (partial-r): 0.2702 [0.2409, 0.299] sex, age, birth date, deprivation index, 16 PCs
PPM010948 PGS002009
(portability-PLR_systolic_BP)
PSS008822|
European Ancestry|
6,337 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Systolic blood pressure, automated reading Partial Correlation (partial-r): 0.2197 [0.1961, 0.243] sex, age, birth date, deprivation index, 16 PCs
PPM010949 PGS002009
(portability-PLR_systolic_BP)
PSS008596|
Greater Middle Eastern Ancestry|
1,151 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Systolic blood pressure, automated reading Partial Correlation (partial-r): 0.2284 [0.1724, 0.2829] sex, age, birth date, deprivation index, 16 PCs
PPM010950 PGS002009
(portability-PLR_systolic_BP)
PSS008374|
South Asian Ancestry|
6,098 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Systolic blood pressure, automated reading Partial Correlation (partial-r): 0.1877 [0.1633, 0.2118] sex, age, birth date, deprivation index, 16 PCs
PPM010951 PGS002009
(portability-PLR_systolic_BP)
PSS008150|
East Asian Ancestry|
1,719 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Systolic blood pressure, automated reading Partial Correlation (partial-r): 0.2163 [0.1705, 0.2612] sex, age, birth date, deprivation index, 16 PCs
PPM010953 PGS002009
(portability-PLR_systolic_BP)
PSS009042|
African Ancestry|
3,850 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Systolic blood pressure, automated reading Partial Correlation (partial-r): 0.1046 [0.0732, 0.1358] sex, age, birth date, deprivation index, 16 PCs
PPM010952 PGS002009
(portability-PLR_systolic_BP)
PSS007938|
African Ancestry|
2,438 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Systolic blood pressure, automated reading Partial Correlation (partial-r): 0.104 [0.0644, 0.1433] sex, age, birth date, deprivation index, 16 PCs
PPM012670 PGS002228
(portability-ldpred2_systolic_BP)
PSS009494|
European Ancestry|
18,717 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Systolic blood pressure, automated reading Partial Correlation (partial-r): 0.2585 [0.2451, 0.2718] sex, age, birth date, deprivation index, 16 PCs
PPM012671 PGS002228
(portability-ldpred2_systolic_BP)
PSS009268|
European Ancestry|
3,930 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Systolic blood pressure, automated reading Partial Correlation (partial-r): 0.2775 [0.2483, 0.3061] sex, age, birth date, deprivation index, 16 PCs
PPM012672 PGS002228
(portability-ldpred2_systolic_BP)
PSS008822|
European Ancestry|
6,337 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Systolic blood pressure, automated reading Partial Correlation (partial-r): 0.2265 [0.203, 0.2498] sex, age, birth date, deprivation index, 16 PCs
PPM012673 PGS002228
(portability-ldpred2_systolic_BP)
PSS008596|
Greater Middle Eastern Ancestry|
1,151 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Systolic blood pressure, automated reading Partial Correlation (partial-r): 0.2233 [0.1672, 0.278] sex, age, birth date, deprivation index, 16 PCs
PPM012674 PGS002228
(portability-ldpred2_systolic_BP)
PSS008374|
South Asian Ancestry|
6,098 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Systolic blood pressure, automated reading Partial Correlation (partial-r): 0.1982 [0.1739, 0.2222] sex, age, birth date, deprivation index, 16 PCs
PPM012675 PGS002228
(portability-ldpred2_systolic_BP)
PSS008150|
East Asian Ancestry|
1,719 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Systolic blood pressure, automated reading Partial Correlation (partial-r): 0.198 [0.1519, 0.2433] sex, age, birth date, deprivation index, 16 PCs
PPM012676 PGS002228
(portability-ldpred2_systolic_BP)
PSS007938|
African Ancestry|
2,438 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Systolic blood pressure, automated reading Partial Correlation (partial-r): 0.0959 [0.0563, 0.1353] sex, age, birth date, deprivation index, 16 PCs
PPM012677 PGS002228
(portability-ldpred2_systolic_BP)
PSS009042|
African Ancestry|
3,850 individuals
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Reported Trait: Systolic blood pressure, automated reading Partial Correlation (partial-r): 0.0994 [0.0679, 0.1306] sex, age, birth date, deprivation index, 16 PCs
PPM012835 PGS002257
(GRS901_SBP)
PSS009574|
European Ancestry|
14,004 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Systolic blood pressure β: 2.06 [1.79, 2.32] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012836 PGS002257
(GRS901_SBP)
PSS009574|
European Ancestry|
14,004 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Diastolic blood pressure β: 1.64 [1.46, 1.81] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012837 PGS002257
(GRS901_SBP)
PSS009574|
European Ancestry|
14,004 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Pulse pressure β: 0.42 [0.25, 0.58] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012838 PGS002257
(GRS901_SBP)
PSS009574|
European Ancestry|
14,004 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Hypertension OR: 1.27 [1.23, 1.32] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012839 PGS002257
(GRS901_SBP)
PSS009575|
African Ancestry|
6,970 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Systolic blood pressure β: 2.38 [1.85, 2.9] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012840 PGS002257
(GRS901_SBP)
PSS009575|
African Ancestry|
6,970 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Diastolic blood pressure β: 1.39 [1.09, 1.7] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012841 PGS002257
(GRS901_SBP)
PSS009575|
African Ancestry|
6,970 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Pulse pressure β: 0.99 [0.65, 1.32] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012842 PGS002257
(GRS901_SBP)
PSS009575|
African Ancestry|
6,970 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Hypertension OR: 1.26 [1.2, 1.33] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012843 PGS002257
(GRS901_SBP)
PSS009576|
South Asian Ancestry|
8,827 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Systolic blood pressure β: 2.58 [2.13, 3.03] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012844 PGS002257
(GRS901_SBP)
PSS009576|
South Asian Ancestry|
8,827 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Diastolic blood pressure β: 1.49 [1.25, 1.74] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012845 PGS002257
(GRS901_SBP)
PSS009576|
South Asian Ancestry|
8,827 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Pulse pressure β: 1.09 [0.8, 1.39] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012846 PGS002257
(GRS901_SBP)
PSS009576|
South Asian Ancestry|
8,827 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Hypertension OR: 1.3 [1.24, 1.36] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012863 PGS002257
(GRS901_SBP)
PSS009584|
European Ancestry|
55,439 individuals
PGP000284 |
Tapela NM et al. Eur J Prev Cardiol (2021)
|Ext.
Reported Trait: Uncontrolled hypertension Odds Ratio (OR, top vs. bottom quintile): 1.7 [1.6, 1.8] age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline 881 SNPs remained after QC
PPM012864 PGS002257
(GRS901_SBP)
PSS009581|
European Ancestry|
55,439 individuals
PGP000284 |
Tapela NM et al. Eur J Prev Cardiol (2021)
|Ext.
Reported Trait: Incident major adverse cardiovascular events in hypertension treatment Hazard Ratio (HR, top vs. bottom quintile): 1.13 [1.04, 1.23] age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline 881 SNPs remained after QC
PPM012865 PGS002257
(GRS901_SBP)
PSS009582|
European Ancestry|
55,439 individuals
PGP000284 |
Tapela NM et al. Eur J Prev Cardiol (2021)
|Ext.
Reported Trait: Incident myocardial infarction in hypertension treatment Hazard Ratio (HR, top vs. bottom quintile): 1.08 [0.97, 1.2] age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline 881 SNPs remained after QC
PPM012866 PGS002257
(GRS901_SBP)
PSS009583|
European Ancestry|
55,439 individuals
PGP000284 |
Tapela NM et al. Eur J Prev Cardiol (2021)
|Ext.
Reported Trait: Incident stroke in hypertension treatment Hazard Ratio (HR, top vs. bottom quintile): 1.22 [1.06, 1.41] age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline 881 SNPs remained after QC
PPM012945 PGS002275
(SBP-PRS)
PSS009627|
European Ancestry|
4,416 individuals
PGP000303 |
Groenland EH et al. Atherosclerosis (2022)
Reported Trait: Systolic blood pressure β: 3.19 [2.6, 3.78] Age, sex, the first 5 principal components, BMI, T2DM, smoking, alcohol use, LDL-cholesterol, eGFR, triglycerides, antihypertensive medication

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS009042 3,850 individuals African unspecified Nigeria (West Africa) UKB
PSS009627 4,416 individuals,
75.0 % Male samples
European UCC-SMART UCC-SMART
PSS008150 1,719 individuals East Asian China (East Asia) UKB
PSS007266 6,409 individuals African unspecified UKB
PSS007267 1,634 individuals East Asian UKB
PSS007268 23,726 individuals European non-white British ancestry UKB
PSS007269 7,640 individuals South Asian UKB
PSS007270 63,823 individuals European white British ancestry UKB Testing cohort (heldout set)
PSS000371 Individuals who have been referred to a child psychiatric outpatient clinic in the Northern Netherlands before the age of 11. We measured weight and height using regularly calibrated equipment (scales and stadiometer models 770 and 214, respectively; Seca, Hamburg, Germany). Body mass index (BMI; in kg/m2) was also calculated. We measured waist circumference at the midpoint between the lower costal margin and the iliac crest. The hip circumference was measured over both trochanter majores (tangible bone on the outside of the hip joint). Waist to hip ratio was also calculated. We performed all measurements in duplicate, and, if the difference between these measurements exceeded a predefined value, a third measurement was performed. All available measurements were used to calculate means. Heart rate, systolic (SBP) and diastolic (DBP) blood pressure were measured in duplicate with a Dinamap Critikon 1846SX (Critikon Inc, Tampa, FL), from which we calculated means. At the third visit, fasting blood sample of participants were drawn for the measurement of glucose (Roche Diagnostics, Basel, Switzerland), insulin (Diagnostic Systems Laboratories Inc, Webster, TX), HbA1c (high performance liquid chromatography, Variant, Bio-Rad), triglycerides, total cholesterol, HDL cholesterol (Roche Diagnostics) and LDL cholesterol (calculated according to Friedewald’s equation5), as well as alanine transaminase (Photometric determination according to the reference method of the International Federation of Clinical Chemistry (IFCC)6) and lipoprotein(a) (Nephelometric method, BN2, DadeBehring). Serum creatinine was measured by photometric determination with the Jaffé method without deproteinisation (Ecoline® MEGA, DiaSys Diagnostic Systems GmbH. Merck). eGFR for adolescents who were younger than 18 years old was calculated using the Schwartz formula.7 High‐sensitivity C‐reactive protein (hsCRP) was determined using an immunonephelometric method, BN2 (CardioPhase hsCRP, Siemens) with a lower detection limit of 0.175 mg/L. Total IgE measurements were performed using the Phadia Immunocap 100 system with fluoroenzyme immunoassay (FEIA). 288 individuals,
69.2 % Male samples
Mean = 15.83 years
Sd = 0.6 years
European TRAILS, TRAILSCC TRAILS Clinical Cohort
PSS008822 6,337 individuals European Italy (South Europe) UKB
PSS000376 We measured weight and height using regularly calibrated equipment (scales and stadiometer models 770 and 214, respectively; Seca, Hamburg, Germany). Body mass index (BMI; in kg/m2) was also calculated. We measured waist circumference at the midpoint between the lower costal margin and the iliac crest. The hip circumference was measured over both trochanter majores (tangible bone on the outside of the hip joint). Waist to hip ratio was also calculated. We performed all measurements in duplicate, and, if the difference between these measurements exceeded a predefined value, a third measurement was performed. All available measurements were used to calculate means. Heart rate, systolic (SBP) and diastolic (DBP) blood pressure were measured in duplicate with a Dinamap Critikon 1846SX (Critikon Inc, Tampa, FL), from which we calculated means. At the third visit, fasting blood sample of participants were drawn for the measurement of glucose (Roche Diagnostics, Basel, Switzerland), insulin (Diagnostic Systems Laboratories Inc, Webster, TX), HbA1c (high performance liquid chromatography, Variant, Bio-Rad), triglycerides, total cholesterol, HDL cholesterol (Roche Diagnostics) and LDL cholesterol (calculated according to Friedewald’s equation5), as well as alanine transaminase (Photometric determination according to the reference method of the International Federation of Clinical Chemistry (IFCC)6) and lipoprotein(a) (Nephelometric method, BN2, DadeBehring). Serum creatinine was measured by photometric determination with the Jaffé method without deproteinisation (Ecoline® MEGA, DiaSys Diagnostic Systems GmbH. Merck). eGFR for adolescents who were younger than 18 years old was calculated using the Schwartz formula.7 High‐sensitivity C‐reactive protein (hsCRP) was determined using an immunonephelometric method, BN2 (CardioPhase hsCRP, Siemens) with a lower detection limit of 0.175 mg/L. Total IgE measurements were performed using the Phadia Immunocap 100 system with fluoroenzyme immunoassay (FEIA). 1,354 individuals,
47.56 % Male samples
Mean = 16.22 years
Sd = 0.66 years
European TRAILS
PSS007938 2,438 individuals African American or Afro-Caribbean Carribean UKB
PSS008596 1,151 individuals Greater Middle Eastern (Middle Eastern, North African or Persian) Iran (Middle East) UKB
PSS009494 18,717 individuals European UK (+ Ireland) UKB
PSS001169 Cases were individuals with hypertension. Of the 27,804 cases, 13,279 had early-onset hypertension (age of onset < 55 years) whilst 14,525 had late-onset hypertension (age of onset ≥ 55 years).
[
  • 27,804 cases
  • , 95,775 controls
]
,
0.0 % Male samples
European
(Finnish)
FinnGen
PSS001170 Cases were individuals with hypertension. Of the 28,113 cases, 14,082 had early-onset hypertension (age of onset < 55 years) whilst 14,031 had late-onset hypertension (age of onset ≥ 55 years).
[
  • 28,113 cases
  • , 67,100 controls
]
,
100.0 % Male samples
European
(Finnish)
FinnGen
PSS009574 14,004 individuals European Airwave
PSS009575 6,970 individuals African unspecified UKB
PSS009576 8,827 individuals South Asian UKB
PSS009268 3,930 individuals European Poland (NE Europe) UKB
PSS008374 6,098 individuals South Asian India (South Asia) UKB
PSS009581 The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. Median = 11.5 years
[
  • 5,596 cases
  • , 49,843 controls
]
,
51.0 % Male samples
Mean = 61.0 years European
(white British)
UKB
PSS009582 The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. Median = 11.5 years
[
  • 3,586 cases
  • , 51,853 controls
]
,
51.0 % Male samples
Mean = 61.0 years European
(white British)
UKB
PSS009583 The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. Median = 11.5 years
[
  • 2,010 cases
  • , 53,429 controls
]
,
51.0 % Male samples
Mean = 61.0 years European
(white British)
UKB
PSS009584 The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. Median = 11.5 years
[
  • 36,114 cases
  • , 19,325 controls
]
,
51.0 % Male samples
Mean = 61.0 years European
(white British)
UKB
PSS001446 Cases were individuals with incident hypertension. Hypertension was defined as persistently high systemic arterial blood pressure based on multiple blood pressure readings (consistent systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) or medical expenses reimbursement history. Diagnoses were based on the International Classification of Diseases (ICD) 8 codes (I1[0-3]/I15/I674) , ICD-9 codes (I1[0-3]/I15/I674), and ICD-10 codes (I1[0-3]/I15/I674). Of the 55,917 cases, 27,361 had early-onset incident hypertension, whilst 28,556 had late-onset incident hypertension. Early-onset and late-onset hypertension were defined as age of onset <55 and ≥55 years, respectively.
[
  • 55,917 cases
  • , 162,837 controls
]
European
(Finnish)
FinnGen
PSS001447 Cases were individuals with incident coronary heart disease (CHD). CHD was defined as Major coronary heart disease event: coronary revascularization (angioplasty or bypass grafting) or myocardial infarction. Diagnoses were based on the International Classification of Diseases (ICD) 8 codes (410/4110) , ICD-9 codes (410), and ICD-10 codes (I200/I21/I22).
[
  • 21,012 cases
  • , 197,780 controls
]
,
44.0 % Male samples
Mean = 58.0 years European
(Finnish)
FinnGen
PSS001448 Cases were individuals with incident cardiovascular disease (CVD). CVD was defined as ard cardiovascular diseases: coronary heart disease or stroke.
[
  • 29,350 cases
  • , 189,442 controls
]
,
44.0 % Male samples
Mean = 58.0 years European
(Finnish)
FinnGen
PSS001449 Cases were individuals with incident stroke. Stroke was defined as stroke, excluding subarachnoid hemorrhage. Diagnoses were based on the International Classification of Diseases (ICD) 8 codes (431/433/434/436) , ICD-9 codes (431/4330A/4331A/4339A/4340A/4341A/4349A/436), and ICD-10 codes (I61/I63/I64 (excluding I636)).
[
  • 11,734 cases
  • , 201,150 controls
]
European
(Finnish)
FinnGen
PSS001450 Cases were individuals with incident hypertension. Hypertension was defined as persistently high systemic arterial blood pressure based on multiple blood pressure readings (consistent systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) or medical expenses reimbursement history. Diagnoses were based on the International Classification of Diseases (ICD) 8 codes (I1[0-3]/I15/I674) , ICD-9 codes (I1[0-3]/I15/I674), and ICD-10 codes (I1[0-3]/I15/I674).
[
  • 725 cases
  • , 9,181 controls
]
European
(Finnish)
FINRISK